Literature DB >> 23107592

Restoration of viral epithelial tropism improves immunogenicity in rabbits and rhesus macaques for a whole virion vaccine of human cytomegalovirus.

Tong-Ming Fu1, Dai Wang, Daniel C Freed, Aimin Tang, Fengsheng Li, Xi He, Suzanne Cole, Sheri Dubey, Adam C Finnefrock, Jan ter Meulen, John W Shiver, Danilo R Casimiro.   

Abstract

Maternal immunity to human cytomegalovirus (HCMV) prior to conception is ~70% protective against congenital transmission and in utero infection of HCMV. Both functional antibodies capable of neutralizing virus and effective T-cells are believed to be important for the protection. Previous HCMV vaccines have rarely been shown able to induce neutralizing antibody titers comparable to those seen in naturally infected HCMV seropositive subjects. Recent studies link a glycoprotein H (gH) complex to receptor-mediated viral entry of endothelial/epithelial cells and leukocytes. This pentameric gH complex, composed of five proteins (gH, gL, UL128, UL130 and UL131 proteins), is notably missing in all HCMV vaccine previously evaluated in clinic. Here we showed that a HCMV virus, with restored expression of the pentameric gH complex, can induce 10-fold higher neutralizing antibody titers than an attenuated AD169 virus or a recombinant glycoprotein B vaccine in multiple animal species in which viral replication is not expected. Encouragingly, the peak neutralizing titers post vaccination in rabbits and monkeys were within 2-4-fold of the levels determined in HCMV seropositive subjects. Functional antibodies by vaccination could further be improved when formulated with a novel adjuvant, and the titers of the antiviral antibodies were sustained in rabbits for over a year after vaccination. These results indicate that the pentameric gH complex is associated with greatly improved functional antibodies following vaccination, and support a vaccine concept based on a nonreplicating whole HCMV with the pentameric gH-associated epithelial tropism restored.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23107592     DOI: 10.1016/j.vaccine.2012.10.053

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  36 in total

Review 1.  Prospects of a vaccine for the prevention of congenital cytomegalovirus disease.

Authors:  Bodo Plachter
Journal:  Med Microbiol Immunol       Date:  2016-08-12       Impact factor: 3.402

2.  Production of Cytomegalovirus Dense Bodies by Scalable Bioprocess Methods Maintains Immunogenicity and Improves Neutralizing Antibody Titers.

Authors:  Kirsten Schneider-Ohrum; Corinne Cayatte; Yi Liu; Zhaoti Wang; Alivelu Irrinki; Floro Cataniag; Nga Nguyen; Stacie Lambert; Hui Liu; Shahin Aslam; Greg Duke; Michael P McCarthy; Louise McCormick
Journal:  J Virol       Date:  2016-10-28       Impact factor: 5.103

3.  Structural and biochemical studies of HCMV gH/gL/gO and Pentamer reveal mutually exclusive cell entry complexes.

Authors:  Claudio Ciferri; Sumana Chandramouli; Danilo Donnarumma; Pavel A Nikitin; Michael A Cianfrocco; Rachel Gerrein; Adam L Feire; Susan W Barnett; Anders E Lilja; Rino Rappuoli; Nathalie Norais; Ethan C Settembre; Andrea Carfi
Journal:  Proc Natl Acad Sci U S A       Date:  2015-01-26       Impact factor: 11.205

4.  Enveloped virus-like particle expression of human cytomegalovirus glycoprotein B antigen induces antibodies with potent and broad neutralizing activity.

Authors:  Marc Kirchmeier; Anne-Catherine Fluckiger; Catalina Soare; Jasminka Bozic; Barthelemy Ontsouka; Tanvir Ahmed; Abebaw Diress; Lenore Pereira; Florian Schödel; Stanley Plotkin; Charlotte Dalba; David Klatzmann; David E Anderson
Journal:  Clin Vaccine Immunol       Date:  2013-12-11

Review 5.  Cytomegalovirus Vaccines: Current Status and Future Prospects.

Authors:  K M Anderholm; C J Bierle; M R Schleiss
Journal:  Drugs       Date:  2016-11       Impact factor: 9.546

6.  Developing a Vaccine against Congenital Cytomegalovirus (CMV) Infection: What Have We Learned from Animal Models? Where Should We Go Next?

Authors:  Mark R Schleiss
Journal:  Future Virol       Date:  2013-12       Impact factor: 1.831

7.  Pentameric complex of viral glycoprotein H is the primary target for potent neutralization by a human cytomegalovirus vaccine.

Authors:  Daniel C Freed; Qi Tang; Aimin Tang; Fengsheng Li; Xi He; Zhao Huang; Weixu Meng; Lin Xia; Adam C Finnefrock; Eberhard Durr; Amy S Espeseth; Danilo R Casimiro; Ningyan Zhang; John W Shiver; Dai Wang; Zhiqiang An; Tong-Ming Fu
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-02       Impact factor: 11.205

8.  A vaccine based on the rhesus cytomegalovirus UL128 complex induces broadly neutralizing antibodies in rhesus macaques.

Authors:  Felix Wussow; Yujuan Yue; Joy Martinez; Jesse D Deere; Jeff Longmate; Andreas Herrmann; Peter A Barry; Don J Diamond
Journal:  J Virol       Date:  2012-11-14       Impact factor: 5.103

9.  A cytomegalovirus DNA vaccine induces antibodies that block viral entry into fibroblasts and epithelial cells.

Authors:  Michael A McVoy; Ronzo Lee; Frances M Saccoccio; Jukka Hartikka; Larry R Smith; Rohit Mahajan; Jian Ben Wang; Xiaohong Cui; Stuart P Adler
Journal:  Vaccine       Date:  2015-10-24       Impact factor: 3.641

10.  Efficient Delivery of Human Cytomegalovirus T Cell Antigens by Attenuated Sendai Virus Vectors.

Authors:  Richard Kiener; Markus Fleischmann; Marian Alexander Wiegand; Niels A W Lemmermann; Christiane Schwegler; Christine Kaufmann; Angelique Renzaho; Simone Thomas; Eva Felder; Hans Helmut Niller; Benedikt Asbach; Ralf Wagner
Journal:  J Virol       Date:  2018-07-17       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.